{
  "items": "34",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "12 Health Care Stocks Moving In Friday's Pre-Market Session",
      "url": "https://www.benzinga.com/insights/movers/25/12/49591844/12-health-care-stocks-moving-in-fridays-pre-market-session",
      "time_published": "20251226T120851",
      "authors": [
        "Benzinga Insights",
        "Benzinga Staff Writer"
      ],
      "summary": "This article details the pre-market movements of 12 health care stocks on Friday, identifying both gainers and losers. Companies like Can Fite Biofarma, Scinai Immunotherapeutics, and Agape ATP saw significant increases, while Biohaven, Athira Pharma, and Adagio Medical Holdings experienced declines. The report provides market cap and percentage change for each listed stock.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/07/24/article-header-background-image.png?quality=85&auto=webp&width=1300",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "Benzinga",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.931939"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.842037"
        }
      ],
      "overall_sentiment_score": -0.708826,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "0.911753",
          "ticker_sentiment_score": "-0.719894",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Adagio Medical Holdings CFO Deborah Kaster Acquires 15,000 Shares",
      "url": "https://www.tradingview.com/news/tradingview:95dbd957c7c27:0-adagio-medical-holdings-cfo-deborah-kaster-acquires-15-000-shares/",
      "time_published": "20251218T190952",
      "authors": [
        "NULL"
      ],
      "summary": "Deborah Kaster, CFO and 10% owner of Adagio Medical Holdings (ADGM), purchased 15,000 shares of common stock on December 16, 2025. The transaction totaled $17,973 at an average price of $1.1982 per share. Following this purchase, Kaster directly owns 15,000 shares in the company.",
      "banner_image": "NULL",
      "source": "TradingView \u2014 Track All Markets",
      "category_within_source": "General",
      "source_domain": "TradingView \u2014 Track All Markets",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.912635"
        },
        {
          "topic": "finance",
          "relevance_score": "0.808264"
        }
      ],
      "overall_sentiment_score": 0.42482,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.403687",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Insider Buying: Deborah Kaster Acquires 15,000 Shares of Adagio Medical Holdings Inc (ADGM)",
      "url": "https://www.gurufocus.com/news/4075887/insider-buying-deborah-kaster-acquires-15000-shares-of-adagio-medical-holdings-inc-adgm?mobile=true",
      "time_published": "20251218T140931",
      "authors": [
        "GuruFocus News"
      ],
      "summary": "On December 16, 2025, Deborah Kaster, CFO of Adagio Medical Holdings Inc (ADGM), purchased 15,000 shares of the company, bringing her total ownership to 15,000 shares. This transaction reflects insider confidence, as there have been two insider buys and no sells over the past year. Shares were trading at $1.20 each at the time of purchase, contributing to a market cap of $25.733 million for the medical technology company.",
      "banner_image": "NULL",
      "source": "GuruFocus",
      "category_within_source": "General",
      "source_domain": "GuruFocus",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.940906"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.835028"
        }
      ],
      "overall_sentiment_score": 0.423314,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.439566",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Adagio Medical Holdings elects directors and approves auditor at annual meeting",
      "url": "https://www.investing.com/news/sec-filings/adagio-medical-holdings-elects-directors-and-approves-auditor-at-annual-meeting-93CH-4411465",
      "time_published": "20251217T190931",
      "authors": [
        "Investing.com"
      ],
      "summary": "Adagio Medical Holdings (NASDAQ:ADGM) recently held its 2025 Annual Meeting of Stockholders, where shareholders elected two directors and ratified WithumSmith+Brown, PC as their independent registered public accounting firm. The company, facing financial challenges with a market capitalization of $26 million, also recently closed a $50 million private placement and appointed Sean Salmon to its board. Lake Street Capital Markets initiated coverage with a Buy rating, citing the company's strong technology in the ventricular tachycardia market.",
      "banner_image": "https://i-invdn-com.investing.com/news/news_six_pile_69x52._800x533_L_1419494215.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.904256"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.826464"
        },
        {
          "topic": "finance",
          "relevance_score": "0.742528"
        }
      ],
      "overall_sentiment_score": 0.10779,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.108415",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI), Fortrea Holdings Inc. (FTRE) and Novan (NOVN)",
      "url": "https://www.theglobeandmail.com/investing/markets/stocks/NOVN/pressreleases/36669023/analysts-offer-insights-on-healthcare-companies-trisalus-life-sciences-tlsi-fortrea-holdings-inc-ftre-and-novan-novn/",
      "time_published": "20251217T140831",
      "authors": [
        "Tipranks"
      ],
      "summary": "Analysts have provided insights on several healthcare companies. TriSalus Life Sciences (TLSI) received a reiterated Buy rating from Lake Street with a $10.00 price target and has a Strong Buy consensus. Fortrea Holdings Inc. (FTRE) was reiterated with a Sell rating by Bank of America Securities, carrying an $8.00 price target and a general analyst consensus of Hold.",
      "banner_image": "NULL",
      "source": "The Globe and Mail",
      "category_within_source": "General",
      "source_domain": "The Globe and Mail",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.926235"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.807037"
        }
      ],
      "overall_sentiment_score": 0.331803,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "0.649230",
          "ticker_sentiment_score": "0.332320",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Adagio Medical Holdings elects directors and approves auditor at annual meeting",
      "url": "https://m.investing.com/news/sec-filings/adagio-medical-holdings-elects-directors-and-approves-auditor-at-annual-meeting-93CH-4411465?ampMode=1",
      "time_published": "20251216T210831",
      "authors": [
        "Investing.com"
      ],
      "summary": "Adagio Medical Holdings, Inc. held its 2025 Annual Meeting of Stockholders, electing Todd Usen and James L. Cox, M.D. to its board and ratifying WithumSmith+Brown, PC as its independent auditor. The company, facing financial challenges, recently closed a $50 million private placement and appointed Sean Salmon to its Board of Directors. Lake Street Capital Markets initiated coverage with a Buy rating.",
      "banner_image": "NULL",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.905538"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.814559"
        }
      ],
      "overall_sentiment_score": 0.005239,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.004502",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CEO Usen Buys 207,315 ($226K) Of Adagio Medical Holdings Inc [ADGM]",
      "url": "https://www.tradingview.com/news/reuters.com,2025-12-15:newsml_WSACmHf0a:0-ceo-usen-buys-207-315-226k-of-adagio-medical-holdings-inc-adgm/",
      "time_published": "20251216T190952",
      "authors": [
        "Refinitiv"
      ],
      "summary": "Usen Todd, Chief Executive Officer of Adagio Medical Holdings Inc (ADGM), purchased 207,315 shares of the company's stock on December 12, 2025. The transaction was valued at approximately $225,973, with shares bought at $1.09 each. This purchase brings his direct holdings to 207,315 shares.",
      "banner_image": "NULL",
      "source": "TradingView \u2014 Track All Markets",
      "category_within_source": "General",
      "source_domain": "TradingView \u2014 Track All Markets",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.931720"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.740385"
        }
      ],
      "overall_sentiment_score": 0.413591,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.391479",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "CEO Todd Usen Acquires 207,315 Shares of Adagio Medical Holdings Inc (ADGM)",
      "url": "https://www.gurufocus.com/news/4070781/ceo-todd-usen-acquires-207315-shares-of-adagio-medical-holdings-inc-adgm?mobile=true",
      "time_published": "20251216T040953",
      "authors": [
        "GuruFocus News"
      ],
      "summary": "Todd Usen, CEO of Adagio Medical Holdings Inc (ADGM), recently purchased 207,315 shares of the company, bringing his total holdings to the same amount. This transaction, occurring on December 12, 2025, reflects his confidence in the company's future, aligning with its current trading value of $1.09 per share and a market cap of $17.422 million. This is the sole insider buy in the past year, with no insider sells recorded.",
      "banner_image": null,
      "source": "GuruFocus",
      "category_within_source": "General",
      "source_domain": "GuruFocus",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.909166"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.730015"
        }
      ],
      "overall_sentiment_score": 0.44925,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.436577",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Usen Todd, CEO of Adagio Medical, buys $225k in Adagio stock",
      "url": "https://www.investing.com/news/insider-trading-news/usen-todd-ceo-of-adagio-medical-buys-225k-in-adagio-stock-93CH-4409603",
      "time_published": "20251215T093400",
      "authors": [
        "Investing.com"
      ],
      "summary": "Adagio Medical CEO Todd Usen recently purchased 207,315 shares of the company's common stock for over $225,000, with trades executed at prices ranging from $0.9258 to $1.14101. This insider transaction comes as Adagio Medical announced a $50 million private placement and the appointment of Sean Salmon to its Board of Directors, with Lake Street Capital Markets initiating coverage with a \"Buy\" rating.",
      "banner_image": "https://i-invdn-com.investing.com/news/news_six_pile_69x52._800x533_L_1419494215.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.921369"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.836902"
        },
        {
          "topic": "finance",
          "relevance_score": "0.705061"
        }
      ],
      "overall_sentiment_score": 0.28245,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.442714",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.648728",
          "ticker_sentiment_score": "0.110379",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Adagio Medical Holdings appoints Sean Salmon to board of directors",
      "url": "https://www.investing.com/news/sec-filings/adagio-medical-holdings-appoints-sean-salmon-to-board-of-directors-93CH-4404756",
      "time_published": "20251212T201016",
      "authors": [
        "Investing.com"
      ],
      "summary": "Adagio Medical Holdings has announced the appointment of Sean Salmon to its board of directors, increasing the board size from six to seven members. Salmon, a former Medtronic executive, will serve as a Class II director until the 2026 annual meeting and will also join the Audit and Compensation Committees. This strategic move follows recent private placements totaling $50 million and $19 million, aimed at supporting FDA submissions and advancing product development.",
      "banner_image": "https://i-invdn-com.investing.com/news/news_six_pile_69x52._800x533_L_1419494215.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.800738"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.728198"
        }
      ],
      "overall_sentiment_score": 0.331842,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.310863",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Adagio Medical Holdings appoints Sean Salmon to board of directors",
      "url": "https://in.investing.com/news/sec-filings/adagio-medical-holdings-appoints-sean-salmon-to-board-of-directors-93CH-5150242",
      "time_published": "20251211T230922",
      "authors": [
        "Investing.com"
      ],
      "summary": "Adagio Medical Holdings has appointed Sean Salmon, former Executive Vice President and President of Medtronic\u2019s Cardiovascular Portfolio, to its board of directors as a Class II director. Salmon will also join the Audit and Compensation Committees. This move comes as the company recently closed a $50 million private placement to support FDA submission activities and advance its new Ultra-Low Temperature Cryoablation catheter.",
      "banner_image": "https://i-invdn-com.investing.com/news/news_six_pile_69x52._800x533_L_1419494215.jpg",
      "source": "Investing.com India",
      "category_within_source": "General",
      "source_domain": "Investing.com India",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.901515"
        },
        {
          "topic": "finance",
          "relevance_score": "0.700018"
        }
      ],
      "overall_sentiment_score": 0.205346,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.323853",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.713311",
          "ticker_sentiment_score": "0.112336",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Adagio Medical Holdings Appoints Sean Salmon to Board of Directors",
      "url": "https://www.tradingview.com/news/tradingview:c57165ecb3751:0-adagio-medical-holdings-appoints-sean-salmon-to-board-of-directors/",
      "time_published": "20251211T220922",
      "authors": [
        "NULL"
      ],
      "summary": "Adagio Medical Holdings, Inc. announced the appointment of Sean Salmon as a Class II director, effective December 11, 2025, expanding its Board to seven members. Salmon, formerly EVP and President at Medtronic, will serve until the 2026 annual meeting and has been appointed to the Audit and Compensation Committees.",
      "banner_image": "NULL",
      "source": "TradingView",
      "category_within_source": "General",
      "source_domain": "TradingView",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.932976"
        },
        {
          "topic": "finance",
          "relevance_score": "0.734474"
        }
      ],
      "overall_sentiment_score": 0.223574,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.210787",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Adagio Medical appoints Medtronic veteran Sean Salmon to board",
      "url": "https://www.investing.com/news/company-news/adagio-medical-appoints-medtronic-veteran-sean-salmon-to-board-93CH-4403335",
      "time_published": "20251211T201017",
      "authors": [
        "Investing.com"
      ],
      "summary": "Adagio Medical Holdings, Inc. (NASDAQ:ADGM) has appointed Sean Salmon, a Medtronic veteran, to its Board of Directors and to its Audit and Compensation Committees. Salmon, who retired from Medtronic recently, brings extensive experience in electrophysiology and ablation markets to Adagio Medical, a company specializing in Ultra-Low Temperature Cryoablation technology for cardiac arrhythmias. This appointment comes as Adagio Medical faces significant financial challenges but has recently closed substantial private placements and reported promising clinical trial results for its vCLAS Cryoablation System.",
      "banner_image": "https://i-invdn-com.investing.com/news/international_newspapers_69x52._800x533_L_1419494241.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.915077"
        },
        {
          "topic": "finance",
          "relevance_score": "0.715488"
        }
      ],
      "overall_sentiment_score": 0.198347,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.295173",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.877350",
          "ticker_sentiment_score": "0.108648",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Adagio Medical (Nasdaq: ADGM) adds Medtronic veteran Sean Salmon to board and committees",
      "url": "https://www.stocktitan.net/news/ADGM/adagio-medical-appoints-industry-veteran-sean-salmon-to-board-of-u3shy81rz15w.html",
      "time_published": "20251211T131000",
      "authors": [
        "NULL"
      ],
      "summary": "Adagio Medical Holdings, Inc. (Nasdaq: ADGM) has appointed Sean Salmon, a former Executive Vice President and President of Medtronic\u2019s Cardiovascular Portfolio, to its Board of Directors, where he will also serve on the Audit and Compensation Committees. Mr. Salmon brings over 20 years of experience from Medtronic, including extensive expertise in electrophysiology, ablation technologies, and commercializing breakthrough medical platforms. His appointment is expected to significantly contribute to Adagio Medical's strategic priorities, including commercial planning and pipeline innovation for its ultralow temperature ablation technology.",
      "banner_image": "NULL",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.916754"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.619642"
        }
      ],
      "overall_sentiment_score": 0.015527,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "0.321736",
          "ticker_sentiment_score": "0.004542",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Lake Street Capital initiates Adagio Medical stock with Buy rating",
      "url": "https://www.investing.com/news/analyst-ratings/lake-street-capital-initiates-adagio-medical-stock-with-buy-rating-93CH-4386298",
      "time_published": "20251203T051016",
      "authors": [
        "Investing.com"
      ],
      "summary": "Lake Street Capital Markets has initiated coverage on Adagio Medical Holdings (NASDAQ:ADGM) with a Buy rating and a $4.00 price target, citing the company's strong technological position in the ventricular tachycardia market. The firm anticipates significant share upside driven by upcoming product development milestones in 2026 and a commercial launch expected in 2027. Despite current lows attributed to \"post-de-SPAC overhang\" and a previously underfunded balance sheet, Lake Street Capital believes Adagio now possesses the capital to execute its strategy, supported by recent private placements totaling up to $69 million.",
      "banner_image": "https://i-invdn-com.investing.com/news/news_six_pile_69x52._800x533_L_1419494215.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.943405"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.818524"
        }
      ],
      "overall_sentiment_score": 0.467893,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.465884",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "ADGM Stock Institutional Owners",
      "url": "https://www.quiverquant.com/stock/ADGM/institutions/",
      "time_published": "20251124T201017",
      "authors": [
        "NULL"
      ],
      "summary": "This article details the institutional ownership and other financial data for Adagio Medical Holdings, Inc. (ADGM). It provides insights into institutional holdings, insider trading activity, patent grants, and analyst ratings, along with backtested strategy performance metrics. The company specializes in catheter ablation technologies for cardiac arrhythmias.",
      "banner_image": "NULL",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.803081"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.700944"
        }
      ],
      "overall_sentiment_score": 0.012461,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "0.991691",
          "ticker_sentiment_score": "0.037808",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNPS",
          "relevance_score": "0.639641",
          "ticker_sentiment_score": "0.005657",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVDA",
          "relevance_score": "0.617880",
          "ticker_sentiment_score": "0.025940",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "12 Health Care Stocks Moving In Friday's Pre-Market Session",
      "url": "https://www.benzinga.com/insights/movers/25/11/48860763/12-health-care-stocks-moving-in-fridays-pre-market-session",
      "time_published": "20251114T220853",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "This article details the pre-market movements of 12 healthcare stocks on a Friday, categorizing them as gainers or losers. Cidara Therapeutics, Invivyd, and Aspire Biopharma Holdings were among the significant gainers, while enVVeno Medical, SeaStar Medical Holding, and Adagio Medical Holdings saw notable declines. The report also mentions recent Q3 earnings releases for some of the companies.",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/11/06/movers_4.jpg?quality=85&auto=webp&width=850",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "Benzinga",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.926107"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.928035"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.836188"
        }
      ],
      "overall_sentiment_score": -0.381065,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.426978",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "$19M Upfront Funds: Adagio Medical Advances vCLAS ULTC, Supports FULCRUM-VT FDA Submission",
      "url": "https://www.stocktitan.net/news/ADGM/adagio-medical-closes-financing-of-19-million-upfront-positions-s16ew2rfetog.html",
      "time_published": "20251108T051017",
      "authors": [],
      "summary": "Adagio Medical Holdings, Inc. (Nasdaq: ADGM) has secured $19 million in financing to advance its vCLAS\u2122 ULTC System for treating ventricular tachycardia. The funds will support FDA Premarket Approval submission for the FULCRUM-VT study, further develop its next-generation ULTC catheter, and expand commercial readiness. This capital infusion is expected to extend the company's cash runway and de-risk execution into key inflection points for its Ultra-Low Temperature Cryoablation technology.",
      "banner_image": "https://www.stocktitan.net/img/logo/stock-titan-logo-header-free.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.922357"
        }
      ],
      "overall_sentiment_score": 0.342059,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.331256",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Adagio Medical Secures $19M for Cryoablation Tech",
      "url": "https://www.tipranks.com/news/company-announcements/adagio-medical-secures-19m-for-cryoablation-tech",
      "time_published": "20251108T051017",
      "authors": [
        "|NULL"
      ],
      "summary": "Adagio Medical Holdings secured $19 million in a private placement to advance its Ultra-Low Temperature Cryoablation technologies, particularly for ventricular tachycardia. These funds will support FDA submissions, clinical experience enhancement, and manufacturing expansion. Despite this funding, TipRanks\u2019 AI Analyst, Spark, rates ADGM as Neutral due to poor financial performance and a bearish technical outlook.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1549769756-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.915365"
        }
      ],
      "overall_sentiment_score": -0.420061,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.424957",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Adagio Medical closes $50 million private placement to fund FDA efforts",
      "url": "https://www.investing.com/news/company-news/adagio-medical-closes-50-million-private-placement-to-fund-fda-efforts-93CH-4296983",
      "time_published": "20251108T051017",
      "authors": [
        "Investing.com"
      ],
      "summary": "Adagio Medical Holdings, Inc. (NASDAQ:ADGM) has secured a $50 million private placement from existing and new healthcare-focused institutional investors to fund FDA submission activities for its vCLAS\u2122 ULTC System and advance its Ultra-Low Temperature Cryoablation (ULTC) catheter. This capital infusion is crucial for the company, which specializes in catheter ablation technologies for cardiac arrhythmias and had generated only $0.32 million in revenue over the last twelve months with an EBITDA of -$30.34 million. The funding will also support the expansion of manufacturing capabilities and extend its cash runway into key development milestones, following the recent completion of enrollment for its FULCRUM-VT U.S. IDE Pivotal Study.",
      "banner_image": "https://i-invdn-com.investing.com/news/international_newspapers_69x52._800x533_L_1419494241.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.948670"
        },
        {
          "topic": "finance",
          "relevance_score": "0.839435"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.705984"
        }
      ],
      "overall_sentiment_score": 0.532822,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.513074",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Adagio Medical Closes Financing of $19 Million Upfront; Positions Company to Advance Purpose-Built Technology for Treatment of Ventricular Tachycardia",
      "url": "https://www.tradingview.com/news/reuters.com,2025:newsml_FWN3VZ0F6:0-adagio-medical-closes-financing-of-19-million-upfront-positions-company-to-advance-purpose-built-technology-for-treatment-of-ventricular-tachycardia/",
      "time_published": "20251108T051017",
      "authors": [
        "NULL"
      ],
      "summary": "Adagio Medical announced the closing of a $19 million upfront financing round. This funding is intended to advance the company's development of purpose-built technology for the treatment of ventricular tachycardia. The news positions the company for further progress in its medical device innovations.",
      "banner_image": "NULL",
      "source": "TradingView",
      "category_within_source": "General",
      "source_domain": "TradingView",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.800648"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.921618"
        }
      ],
      "overall_sentiment_score": 0.408446,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.431245",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Adagio Medical Holdings sets date for 2025 annual meeting and proposal deadlines",
      "url": "https://www.investing.com/news/sec-filings/adagio-medical-holdings-sets-date-for-2025-annual-meeting-and-proposal-deadlines-93CH-4308786",
      "time_published": "20251024T164400",
      "authors": [
        "Investing.com"
      ],
      "summary": "Adagio Medical Holdings, Inc. announced the scheduling of its 2025 annual meeting of stockholders for December 15, 2025, with a record date of October 31, 2025. The company also set deadlines for stockholder proposals and director nominations due to not holding a 2024 annual meeting. This announcement comes amid recent financial activities, including a $50 million private placement and positive clinical developments for its vCLAS\u2122 ULTC System.",
      "banner_image": null,
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.921999"
        }
      ],
      "overall_sentiment_score": 0.125561,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.117620",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Adagio Medical Holdings, Inc. Closes $19 Million Financing",
      "url": "https://www.tradingview.com/news/tradingview:cc587417a81e4:0-adagio-medical-holdings-inc-closes-19-million-financing/",
      "time_published": "20251020T000000",
      "authors": [],
      "summary": "Adagio Medical Holdings, Inc. announced the closing of a $19 million private placement on October 20, 2025. These funds are designated to support FDA submission for their vCLAS ULTC System, advance next-gen ULTC catheter development, build awareness of ULTC's benefits for VT patients, expand manufacturing and commercial readiness, and strengthen overall corporate operations. The announcement was based on an original SEC Filing.",
      "banner_image": null,
      "source": "TradingView",
      "category_within_source": "General",
      "source_domain": "TradingView",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.949025"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.839340"
        },
        {
          "topic": "finance",
          "relevance_score": "0.749067"
        }
      ],
      "overall_sentiment_score": 0.462429,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.451744",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Adagio Medical raises $19 million in private placement",
      "url": "https://www.investing.com/news/company-news/adagio-medical-raises-19-million-in-private-placement-93CH-4289713",
      "time_published": "20251015T220832",
      "authors": [
        "Investing.com"
      ],
      "summary": "Adagio Medical Holdings, Inc. (NASDAQ:ADGM) has secured approximately $19 million in upfront proceeds through a private placement with accredited investors, with potential for an additional $31 million. This funding is crucial for the company, which reported a negative free cash flow of $29.3 million, and will be used for working capital and advancing its catheter ablation technologies for cardiac arrhythmias. The transaction is backed by Perceptive Advisors, LLC, and other healthcare-dedicated and institutional investors, with Piper Sandler acting as the sole placement agent.",
      "banner_image": "https://i-invdn-com.investing.com/news/news_headline_rolled_69x52._800x533_L_1419494221.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.946685"
        },
        {
          "topic": "finance",
          "relevance_score": "0.847982"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.718512"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.614208"
        }
      ],
      "overall_sentiment_score": 0.226105,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.390176",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "PLTR",
          "relevance_score": "0.646711",
          "ticker_sentiment_score": "0.003335",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Adagio Medical raises $19 million in private placement By Investing.com - Investing.com Nigeria",
      "url": "https://ng.investing.com/news/company-news/adagio-medical-raises-19-million-in-private-placement-93CH-2147079",
      "time_published": "20251015T202631",
      "authors": [
        "Investing.com"
      ],
      "summary": "Adagio Medical has successfully raised $19 million through a private placement. This funding round is expected to support the company's operations and potentially advance its medical device development.",
      "banner_image": null,
      "source": "Investing.com Nigeria",
      "category_within_source": "General",
      "source_domain": "Investing.com Nigeria",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.728646"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.623921"
        }
      ],
      "overall_sentiment_score": 0.045086,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "0.337119",
          "ticker_sentiment_score": "0.041849",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Adagio Medical Announces Pricing of $50M Private Placement - Orange County Business Journal",
      "url": "https://www.ocbj.com/healthcare/adagio-medical-announces-pricing-of-50m-private-placement/",
      "time_published": "20251015T180358",
      "authors": [
        "Yuika Yoshida"
      ],
      "summary": "Adagio Medical Holdings Inc. announced the pricing of a $50 million private placement. The medical device maker, based in Laguna Hills, intends to use the proceeds for working capital and general corporate purposes, including clinical and product development activities for its cardiac arrhythmia treatment system. The private placement is being led by an affiliate of existing investor Perceptive Advisors LLC.",
      "banner_image": null,
      "source": "Orange County Business Journal",
      "category_within_source": "General",
      "source_domain": "Orange County Business Journal",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.848277"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.724212"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.603641"
        }
      ],
      "overall_sentiment_score": 0.001864,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "0.330733",
          "ticker_sentiment_score": "0.032320",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Adagio Medical Raises $19M in Private Placement - TipRanks",
      "url": "https://www.tipranks.com/news/company-announcements/adagio-medical-raises-19m-in-private-placement",
      "time_published": "20251015T123336",
      "authors": [
        "TipRanks Auto-Generated Newsdesk"
      ],
      "summary": "Adagio Medical Holdings announced a private placement to raise $19 million upfront, with potential for an additional $31 million, through the issuance of common stock and warrants. The funds will support working capital, clinical advancements, and product development for its cardiac arrhythmia treatment technologies. An analyst maintained a Hold rating on ADGM stock with a $2.00 price target, while TipRanks' AI Analyst, Spark, also rates ADGM as Neutral due to consistent losses and negative cash flows.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1279492897-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.927247"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.810719"
        },
        {
          "topic": "finance",
          "relevance_score": "0.717662"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.602649"
        }
      ],
      "overall_sentiment_score": 0.01708,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "0.316724",
          "ticker_sentiment_score": "0.040573",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Adagio Medical Announces Pricing of up to $50 Million Private Placement of Securities - MarketScreener",
      "url": "https://www.marketscreener.com/news/adagio-medical-announces-pricing-of-up-to-50-million-private-placement-of-securities-ce7d5adfd989f32d",
      "time_published": "20251015T120505",
      "authors": [
        "Business Wire"
      ],
      "summary": "Adagio Medical Holdings, Inc. announced a private placement aiming to raise up to $50 million, with $19 million in upfront proceeds and potential additional funds from warrant exercises. The financing, led by Perceptive Advisors, will support working capital and the company's clinical and product development activities for its catheter ablation technologies. The private placement involves shares of common stock, pre-funded warrants, and accompanying warrants, with varying exercise conditions tied to clinical trial results and FDA approvals.",
      "banner_image": null,
      "source": "MarketScreener",
      "category_within_source": "General",
      "source_domain": "MarketScreener",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.701902"
        },
        {
          "topic": "finance",
          "relevance_score": "0.518878"
        }
      ],
      "overall_sentiment_score": 0.035657,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "0.336290",
          "ticker_sentiment_score": "0.016418",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Adagio Medical Announces Pricing of up to $50 Million Private Placement of Securities",
      "url": "https://www.stocktitan.net/news/ADGM/adagio-medical-announces-pricing-of-up-to-50-million-private-acj5vg9f7qj6.html",
      "time_published": "20251015T080000",
      "authors": [],
      "summary": "Adagio Medical Holdings, Inc. (Nasdaq: ADGM) announced a private placement of securities expected to generate approximately $19 million in upfront proceeds and potentially up to $31 million more from warrant exercises. The financing is led by an affiliate of Perceptive Advisors, LLC, with proceeds earmarked for working capital, clinical, and product development activities. The private placement involves the issuance of common stock (or pre-funded warrants) and accompanying warrants with varying exercise conditions tied to clinical trial results and FDA approvals.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.947352"
        }
      ],
      "overall_sentiment_score": 0.105654,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.102863",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "97.4% Acute Clinical Success: Adagio Medical ULTC Eliminates VT in 96.7% of 207 Patients",
      "url": "https://www.stocktitan.net/news/ADGM/adagio-medical-unveils-preliminary-acute-results-from-fulcrum-vt-u-s-ven9gmvz5a9v.html",
      "time_published": "20251010T154000",
      "authors": [],
      "summary": "Adagio Medical Holdings, Inc. (Nasdaq: ADGM) announced preliminary acute results from its FULCRUM-VT study for Ultralow Temperature Cryoablation (ULTC) in treating Ventricular Tachycardia (VT). The study demonstrated a 97.4% acute clinical success rate and eliminated all clinically-relevant VTs in 96.7% of 207 patients. These promising results were presented at the 20th Annual International Symposium on Ventricular Arrhythmias.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.813674"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.710186"
        }
      ],
      "overall_sentiment_score": 0.613248,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.572148",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Adagio Medical Reports Promising Results from FULCRUM-VT Study",
      "url": "https://www.tipranks.com/news/company-announcements/adagio-medical-reports-promising-results-from-fulcrum-vt-study",
      "time_published": "20251010T000000",
      "authors": [
        "TipRanks Auto-Generated Newsdesk"
      ],
      "summary": "Adagio Medical announced promising preliminary results from its FULCRUM-VT Study, demonstrating a 97.4% acute clinical success rate for its Ultralow Temperature Cryoablation (ULTC) technology in treating Sustained Monomorphic Ventricular Tachycardia (SMVT). The study involved 207 patients and highlighted a favorable safety profile, with further results anticipated at the Heart Rhythm 2026 conference. Despite these positive clinical findings, TipRanks\u2019 AI Analyst, Spark, notes significant financial challenges for the company.",
      "banner_image": null,
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.922529"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.806631"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.744079"
        }
      ],
      "overall_sentiment_score": 0.226199,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.242680",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "ADGM Stock Flying High: Investment Opportunity?",
      "url": "https://stockstotrade.com/news/adagio-medical-holdings-inc-adgm-news-2025_04_17/",
      "time_published": "20250417T100500",
      "authors": [
        "Tim Bohen",
        "Ben Sturgill",
        "Ellis Hobbs"
      ],
      "summary": "Adagio Medical Holdings Inc (ADGM) has seen a significant stock surge of 158.88% due to investor optimism driven by management changes, a medical technology breakthrough, strategic alliances, and unexpected quarterly earnings increases. Despite capital challenges and negative profitability metrics like an EBIT margin of -3,315.9%, the company maintains strong liquidity and high price-to-sales ratios. The article suggests ADGM offers an uncertain yet promising path for traders given its recent innovations and collaborations.",
      "banner_image": null,
      "source": "StocksToTrade",
      "category_within_source": "General",
      "source_domain": "StocksToTrade",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.919762"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.936129"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.812706"
        },
        {
          "topic": "finance",
          "relevance_score": "0.713685"
        }
      ],
      "overall_sentiment_score": 0.320496,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.426090",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "WDC",
          "relevance_score": "0.586369",
          "ticker_sentiment_score": "0.221135",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Adagio Medical Holdings Inc (ADGM) reports earnings",
      "url": "https://qz.com/adagio-medical-holdings-inc-adgm-reports-earnings-1851772911",
      "time_published": "20250327T000000",
      "authors": [
        "Quartz Intelligence Newsroom"
      ],
      "summary": "Adagio Medical Holdings Inc (ADGM) filed its annual 10-K report for the fiscal year ended December 31, 2024, detailing its focus on cardiac arrhythmia treatments using ULTC technology. The company reported a net loss of $53.8 million for the latter half of 2024 and $21.3 million for the first half, alongside a revenue of $0.6 million, a 101% increase attributed to consumable sales. Significant financial events included a Business Combination, impairment charges, and a balance of $20.6 million in cash and cash equivalents, with an anticipation of needing additional capital.",
      "banner_image": "NULL",
      "source": "qz.com",
      "category_within_source": "General",
      "source_domain": "qz.com",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.900178"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.848124"
        },
        {
          "topic": "finance",
          "relevance_score": "0.741552"
        },
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.611081"
        }
      ],
      "overall_sentiment_score": -0.417556,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.427902",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Adagio Medical to restructure, reduce workforce",
      "url": "https://www.massdevice.com/adagio-medical-to-restructure-reduce-workforce/",
      "time_published": "20250228T051017",
      "authors": [
        "Sean Whooley"
      ],
      "summary": "Adagio Medical (Nasdaq:ADGM) is undertaking a corporate restructuring and workforce reduction to prioritize its FULCRUM-VT pivotal FDA investigational device exemption (IDE) clinical trial and a new product design optimization program. The company will pause its limited European launch of vCLAS to focus on these critical priorities. This strategic shift aims to position Adagio as a leader in ventricular tachycardia solutions, despite the difficult decision to part with some employees.",
      "banner_image": "https://wtwh-marketing.s3.amazonaws.com/wp-content/uploads/massdevice/2018/10/10150545/adagio-large-300x195.jpg",
      "source": "MassDevice",
      "category_within_source": "General",
      "source_domain": "MassDevice",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.900500"
        },
        {
          "topic": "finance",
          "relevance_score": "0.727360"
        }
      ],
      "overall_sentiment_score": -0.096329,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADGM",
          "relevance_score": "0.310794",
          "ticker_sentiment_score": "0.006878",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.640623",
          "ticker_sentiment_score": "-0.132008",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.568537",
          "ticker_sentiment_score": "-0.139193",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    }
  ]
}